How to Get Zetia (Ezetimibe) in New Hampshire

What Is Ezetimibe and Why New Hampshire Patients Use It

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, cutting dietary and biliary cholesterol absorption by roughly 54% [1]. The result is a reliable 13 to 20% reduction in LDL-C as monotherapy and an additional 21 to 27% reduction when added to a statin [2]. For New Hampshire adults who cannot tolerate high-intensity statins, or who have not hit their LDL target on a statin alone, ezetimibe is a logical next step.

The FDA approved ezetimibe (Zetia) for primary hypercholesterolemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia [3]. The standard dose is 10 mg orally once daily, taken with or without food, at any time of day [3].

New Hampshire ranks above the national median for cardiovascular disease mortality in adults 55 to 74, according to CDC WONDER data [4]. That context makes lipid-lowering access genuinely consequential, not merely a convenience question.

The IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg after acute coronary syndrome lowered median LDL-C from 69.5 mg/dL to 53.7 mg/dL and reduced the primary composite cardiovascular endpoint by a statistically significant 6.4% relative risk reduction (absolute risk reduction 2.0 percentage points, P=0.016) over a median 6-year follow-up [5]. That trial was the first randomized controlled evidence that non-statin LDL lowering translates into fewer cardiac events.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD, ezetimibe can be added to maximally tolerated statin therapy when LDL-C remains above threshold" [6]. NH clinicians routinely reference this guidance when deciding whether to add ezetimibe.

Who Can Prescribe Ezetimibe in New Hampshire

Any licensed prescriber in good standing with the New Hampshire Board of Medicine, Board of Nursing, or Board of Pharmacy may write a Zetia prescription. That includes physicians (MD or DO), nurse practitioners (NP), and physician assistants (PA). New Hampshire grants NPs full practice authority under RSA 326-B, meaning NPs may prescribe Schedule II through V controlled substances and non-controlled medications without a physician co-signature [7]. PAs require a supervising agreement, but that agreement does not need to be drug-specific [8].

Telehealth providers must hold an active NH license or qualify under the Interstate Medical Licensure Compact. As of 2024, New Hampshire participates in the Nurse Licensure Compact (NLC), so nurses practicing telehealth from another NLC state may see NH patients without a separate NH license [9].

A cardiologist, lipidologist, internist, or family medicine physician can all legally prescribe ezetimibe. Most NH patients receive their first Zetia prescription from a primary care provider rather than a specialist. Referral to a cardiologist becomes more common when the patient has established ASCVD or familial hypercholesterolemia.

The HealthRX NH Prescriber-Match Framework:

1. LDL above goal on max-tolerated statin, no prior cardiac event: start with primary care or telehealth NP.
2. Prior MI, ACS, or LDL above 190 mg/dL without statin response: request cardiology or lipidology referral.
3. Insurance requires specialist notation for prior authorization: telehealth cardiologist visit satisfies most NH commercial payer policies.

Labs Required Before Starting Ezetimibe in New Hampshire

A fasting lipid panel is the minimum required lab before any NH prescriber will write ezetimibe. The panel should include total cholesterol, LDL-C (calculated or direct), HDL-C, and triglycerides, ideally drawn after a 9 to 12 hour fast [10]. Most NH Quest Diagnostics and LabCorp sites can process a fasting panel within 24 to 48 hours.

A liver function test (ALT, AST) is not formally required by the FDA label, but many NH clinicians order it at baseline because ezetimibe undergoes hepatic glucuronidation and is not recommended in patients with moderate to severe hepatic impairment [3]. The NCEP ATP III guidelines historically included liver enzyme monitoring; current ACC/AHA 2022 guidance does not mandate routine ALT monitoring for ezetimibe alone, but individual clinicians differ [6].

If a patient is adding ezetimibe to an existing statin, creatine kinase (CK) and a complete metabolic panel are sometimes ordered to document a clean baseline before the regimen change [11]. The Endocrine Society's 2020 dyslipidemia clinical practice guideline recommends obtaining a baseline lipid panel no more than 12 weeks before initiating lipid-lowering therapy to reflect current metabolic status [12].

A repeat fasting lipid panel 6 to 8 weeks after starting ezetimibe is standard practice to confirm the LDL response and guide further dose titration or additional therapy [6].

How to Get a Zetia Prescription Through Telehealth in New Hampshire

New Hampshire explicitly permits telehealth prescribing of non-controlled medications, including ezetimibe, under RSA 329:1-d and the NH Telehealth Act of 2021 [13]. The provider must establish a valid patient-provider relationship, which in NH requires a synchronous audio-video visit or, in some circumstances, an asynchronous review of sufficient clinical data.

The typical telehealth workflow for ezetimibe in NH runs as follows. First, the patient completes an intake form disclosing cardiovascular history, current medications, and recent labs. Second, a licensed NH provider reviews the submitted lipid panel and conducts a brief video consultation, usually 15 to 20 minutes. Third, the provider sends the prescription electronically to the patient's preferred NH pharmacy. Most telehealth platforms complete this process within 24 to 72 hours of the initial visit.

Ryan Gupta, MD, board-certified in internal medicine, described the telehealth model for lipid management: "For a patient who already has a recent lipid panel and no contraindications, an ezetimibe prescription requires about the same clinical workload as renewing a blood pressure medication. Telehealth eliminates the travel barrier without sacrificing the clinical assessment." [14]

Patients should confirm that their telehealth provider holds an active NH license before booking. Platforms that operate across multiple states sometimes route patients to out-of-state providers who lack NH licensure, which would make any NH prescription invalid.

The American Telemedicine Association notes that asynchronous "store-and-forward" models carry higher regulatory risk for controlled substances but are generally acceptable for non-controlled lipid medications when the patient has an established chart and recent labs [15].

Pharmacy Options in New Hampshire for Ezetimibe

Ezetimibe 10 mg is available at virtually every retail pharmacy chain in New Hampshire, including CVS, Walgreens, Hannaford Pharmacy, Shaw's Pharmacy, and Walmart Pharmacy. Independent community pharmacies in Manchester, Nashua, Concord, and smaller NH towns also stock it routinely.

Generic ezetimibe has been available since 2017, following patent expiration. The GoodRx cash price in NH zip codes ranges from roughly $13 to $32 for a 30-day supply as of mid-2025, depending on the dispensing pharmacy and coupon applied [16]. The branded Zetia runs significantly higher, often $290 to $350 per month, making generic substitution the default choice for most uninsured or underinsured patients.

Mail-order pharmacies licensed in New Hampshire, including Express Scripts and CVS Caremark, can dispense a 90-day supply, typically at a lower per-unit cost than retail. Patients using NH Medicaid should confirm current formulary status directly with their managed care organization, as ezetimibe has been classified as non-covered for standard hyperlipidemia in the NH Medicaid fee-for-service formulary [17].

503A compounding pharmacies licensed by the NH Board of Pharmacy may prepare ezetimibe in customized formulations (such as oral suspensions for patients with swallowing difficulties), provided the preparation uses USP-grade active pharmaceutical ingredient and meets New Hampshire compounding regulations under RSA 318 [18]. Compounded ezetimibe is not bioequivalent-tested against branded Zetia, so clinical monitoring after a formulation switch is advisable.

Prior Authorization in New Hampshire: What Documentation You Need

Most commercial health plans operating in New Hampshire (Anthem BCBS NH, Harvard Pilgrim, Cigna, Aetna) require prior authorization (PA) for branded Zetia and, in some cases, for generic ezetimibe depending on the plan's formulary tier. The PA requirement is driven by formulary management, not clinical skepticism about the drug.

Common documentation requirements for a Zetia PA in NH include: a current fasting lipid panel (within 12 months), documentation of an adequate trial of at least one statin (typically 90 days at a guideline-recommended dose), a reason for statin insufficiency or intolerance, and the treating provider's assessment of ASCVD risk category [19]. Some plans additionally require evidence that the patient's LDL-C remains above their individualized target despite statin therapy.

The 2022 ACC/AHA Cholesterol Guideline defines LDL-C thresholds by risk tier: for very high-risk ASCVD patients, the threshold for adding non-statin therapy is LDL-C at or above 70 mg/dL; for high-risk primary prevention, it is LDL-C at or above 100 mg/dL [6]. Submitting these specific numeric thresholds in the PA letter, rather than a generic clinical summary, meaningfully improves approval rates.

NH law under RSA 420-J:8-a requires commercial insurers to process urgent PA requests within 72 hours and standard PA requests within 3 business days [20]. If a PA is denied, the patient has the right to an internal appeal and, if that fails, an external independent review under the NH Insurance Department's Consumer Services division [21].

For NH Medicaid enrollees, ezetimibe is currently not covered as a primary benefit for uncomplicated hyperlipidemia. A prescriber may submit a "prior authorization exception" request with supporting documentation of ASCVD diagnosis or familial hypercholesterolemia, which occasionally results in coverage approval [17].

Transferring an Existing Zetia Prescription to New Hampshire

Patients relocating to New Hampshire or temporarily residing in the state may transfer a valid ezetimibe prescription from another state's retail pharmacy to an NH pharmacy. Federal law and NH pharmacy regulations allow a one-time transfer of a non-controlled substance prescription between licensed pharmacies [22]. The receiving NH pharmacy must obtain the original prescription information directly from the dispensing pharmacy; a patient-held paper copy alone is not sufficient for most retail transfers.

If the original prescription was written by an out-of-state provider who is not licensed in NH and the prescription has not yet been dispensed, the prescription may not be valid in NH. The patient should request a new prescription from an NH-licensed provider, which can be obtained via a telehealth visit in most cases.

Patients using mail-order pharmacies should update their mailing address with the pharmacy and confirm that the pharmacy holds an NH permit to dispense by mail. Most national mail-order pharmacies hold multi-state permits and can continue shipping to an NH address without a new prescription.

Ezetimibe Dosing, Side Effects, and Drug Interactions

The approved adult dose is ezetimibe 10 mg once daily, taken at any time of day, without regard to food [3]. No dose adjustment is required for renal impairment of any degree. Dose adjustment is also not required for mild hepatic impairment (Child-Pugh score A), but ezetimibe should be avoided in patients with moderate to severe hepatic impairment [3].

The most commonly reported adverse effects in clinical trials were upper respiratory infection (4.3% vs. 3.2% placebo), diarrhea (4.1% vs. 3.7% placebo), arthralgia (3.0% vs. 2.2% placebo), and sinusitis (3.0% vs. 2.8% placebo) [3]. Myopathy is rare with ezetimibe monotherapy but may increase modestly when combined with high-dose statins, particularly simvastatin 80 mg, a dose the FDA restricted in 2011 [23].

Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption by roughly 55% when co-administered; ezetimibe should be taken either 2 hours before or 4 hours after a bile acid sequestrant [3]. Fibrates increase the cholesterol content in bile, which may raise the risk of cholelithiasis; concurrent use of ezetimibe with fenofibrate is listed in the label as requiring clinical monitoring [3]. Cyclosporine significantly increases ezetimibe plasma levels, and the combination requires careful monitoring of both drugs [24].

Drug interactions with the cytochrome P450 system are minimal because ezetimibe is not a CYP substrate, inhibitor, or inducer. This makes it particularly useful for patients on complex polypharmacy regimens [25].

Monitoring After Starting Ezetimibe in New Hampshire

A repeat fasting lipid panel at 6 to 8 weeks after initiation confirms the LDL response. If the LDL reduction is less than 15%, the clinician should assess adherence, timing of the dose relative to bile acid sequestrant use, and whether the patient's dietary cholesterol intake has changed substantially [6].

The ACC/AHA 2022 guideline recommends annual lipid panels once the patient is at goal [6]. Some NH commercial plans require an annual lab result to continue prior authorization approval for ezetimibe; patients should verify this requirement with their insurer to avoid an unexpected coverage lapse.

If a patient on ezetimibe plus a statin develops unexplained muscle pain or weakness, CK should be measured promptly and statin-related myopathy should be considered before attributing the symptom to ezetimibe [11]. A 2021 Cochrane review of ezetimibe-statin combination trials (41 RCTs, N=27,168) found that the combination did not produce a significantly higher rate of myopathy than statin monotherapy alone (risk ratio 1.03 to 95% CI 0.85 to 1.25) [26].

Liver enzyme elevations above 3 times the upper limit of normal occurred in 1.3% of patients receiving ezetimibe plus a statin in IMPROVE-IT, compared to 1.1% in the statin-only group [5]. Routine periodic liver function testing beyond the baseline check is not mandated by current guidelines but remains common practice among NH clinicians, particularly in the first year of combination therapy.

After two consecutive on-goal lipid panels, most NH prescribers extend the monitoring interval to every 12 months, with earlier reassessment if the patient changes other lipid-affecting medications, gains significant weight, or develops new metabolic conditions such as type 2 diabetes [6].